
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Sanofi ADR (SNY)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SNY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $62.17
1 Year Target Price $62.17
5 | Strong Buy |
3 | Buy |
3 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.73% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 122.15B USD | Price to earnings Ratio 16.65 | 1Y Target Price 62.17 |
Price to earnings Ratio 16.65 | 1Y Target Price 62.17 | ||
Volume (30-day avg) 11 | Beta 0.41 | 52 Weeks Range 43.86 - 57.57 | Updated Date 08/29/2025 |
52 Weeks Range 43.86 - 57.57 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 7.82% | Basic EPS (TTM) 3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.95% | Operating Margin (TTM) 18% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 9% |
Valuation
Trailing PE 16.65 | Forward PE 11.15 | Enterprise Value 130835607051 | Price to Sales(TTM) 2.67 |
Enterprise Value 130835607051 | Price to Sales(TTM) 2.67 | ||
Enterprise Value to Revenue 2.46 | Enterprise Value to EBITDA 8.92 | Shares Outstanding 2438960128 | Shares Floating 1096299469 |
Shares Outstanding 2438960128 | Shares Floating 1096299469 | ||
Percent Insiders - | Percent Institutions 10.28 |
Upturn AI SWOT
Sanofi ADR

Company Overview
History and Background
Sanofi ADR represents the American Depositary Receipt of Sanofi, a French multinational pharmaceutical company headquartered in Paris. Founded in 1994 through the merger of Synthu00e9labo and Sanofi, it has grown through acquisitions and R&D to become a leading global healthcare player.
Core Business Areas
- Pharmaceuticals: Focuses on prescription drugs for various therapeutic areas, including cardiovascular, diabetes, oncology, and immunology.
- Vaccines (Sanofi Pasteur): Develops and manufactures vaccines for infectious diseases like influenza, polio, and meningitis.
- Consumer Healthcare: Offers over-the-counter medications and health products for pain relief, allergy, digestive health, and personal care.
Leadership and Structure
Sanofi is led by a CEO and a management board, with a supervisory board overseeing strategic direction. The company operates globally with regional and functional divisions.
Top Products and Market Share
Key Offerings
- Dupixent: A monoclonal antibody used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Generated significant revenue growth. Competitors: Amgen's Tezspire, Regeneron's Rinvoq.
- Influenza Vaccines: Sanofi Pasteur is a major player in the influenza vaccine market. Competitors: GSK, CSL Seqirus.
- Lantus: A long-acting insulin analog used to treat diabetes (biosimilars now available). Competitors: Novo Nordisk, Eli Lilly.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and patent protection. Growth is driven by aging populations, increasing healthcare spending, and innovative therapies.
Positioning
Sanofi is a diversified pharmaceutical company with a strong presence in vaccines and specialty care. Its competitive advantages include a broad product portfolio, global reach, and R&D capabilities.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be worth over $1.4 trillion. Sanofi targets specific segments of this market including immunology, vaccines and specialty care. Sanofi is well positioned within its target markets.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Global presence and distribution network
- Strong R&D capabilities
- Leading position in vaccines
- Established brand reputation
Weaknesses
- Patent expirations
- Dependence on key products
- Exposure to regulatory risks
- Competition from biosimilars
- High R&D costs
Opportunities
- Developing innovative therapies
- Expanding into emerging markets
- Acquiring promising assets
- Partnering with biotech companies
- Increasing demand for vaccines
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Economic downturns
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- LLY
Competitive Landscape
Sanofi competes with other large pharmaceutical companies on innovation, pricing, and market access. Its strengths include a diversified portfolio and global presence, while its weaknesses include patent expirations and regulatory risks.
Major Acquisitions
Translate Bio
- Year: 2021
- Acquisition Price (USD millions): 3200
- Strategic Rationale: To expand Sanofi's mRNA technology capabilities and accelerate vaccine and therapeutic development.
Growth Trajectory and Initiatives
Historical Growth: Sanofi's growth has been driven by acquisitions, new product launches, and geographic expansion. However, patent expirations have created headwinds.
Future Projections: Analysts expect Sanofi to achieve moderate revenue growth in the coming years, driven by new product launches and emerging markets. Earnings growth is expected to be higher due to cost-cutting initiatives.
Recent Initiatives: Sanofi has been focusing on developing innovative therapies in areas like immunology and oncology. It has also been streamlining its operations and investing in digital technologies.
Summary
Sanofi is a large, diversified pharmaceutical company with a strong global presence. The company is well-positioned in vaccines and specialty care, but faces challenges from patent expirations and competition. Key growth drivers include new product launches and expansion into emerging markets. Sanofi needs to continue investing in R&D and managing its cost structure to maintain its competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Financial News Outlets (e.g., Reuters, Bloomberg)
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanofi ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2002-07-01 | CEO & Director Mr. Paul Hudson | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 82878 | Website https://www.sanofi.com |
Full time employees 82878 | Website https://www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.